These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35977582)

  • 1. From vaccines to nanovaccines: A promising strategy to revolutionize rheumatoid arthritis treatment.
    Zhang N; Li M; Hou Z; Ma L; Younas A; Wang Z; Jiang X; Gao J
    J Control Release; 2022 Oct; 350():107-121. PubMed ID: 35977582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanovaccines: A game changing approach in the fight against infectious diseases.
    Priyanka ; Abusalah MAH; Chopra H; Sharma A; Mustafa SA; Choudhary OP; Sharma M; Dhawan M; Khosla R; Loshali A; Sundriyal A; Saini J
    Biomed Pharmacother; 2023 Nov; 167():115597. PubMed ID: 37783148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current and future role of nanovaccines in HIV-1 vaccine development.
    Karch CP; Matyas GR
    Expert Rev Vaccines; 2021 Aug; 20(8):935-944. PubMed ID: 34184607
    [No Abstract]   [Full Text] [Related]  

  • 4. Advancements in prophylactic and therapeutic nanovaccines.
    Bhardwaj P; Bhatia E; Sharma S; Ahamad N; Banerjee R
    Acta Biomater; 2020 May; 108():1-21. PubMed ID: 32268235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis.
    Rahman M; Beg S; Sharma G; Saini S; Rub RA; Aneja P; Anwar F; Alam MA; Kumar V
    Recent Pat Antiinfect Drug Discov; 2016; 11(1):3-15. PubMed ID: 27193030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines.
    Zimmerman DH; Szekanecz Z; Markovics A; Rosenthal KS; Carambula RE; Mikecz K
    Front Immunol; 2024; 15():1334281. PubMed ID: 38510240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node-targeting nanovaccines for cancer immunotherapy.
    Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
    J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Glance on Nanovaccine: A Potential Approach for Disease Prevention.
    Garg A; Agrawal R; Chopra H; Singh T; Chaudhary R; Tankara A
    Curr Pharm Biotechnol; 2024; 25(11):1406-1418. PubMed ID: 37861010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis.
    Rahman M; Beg S; Anwar F; Kumar V; Ubale R; Addo RT; Ali R; Akhter S
    Crit Rev Ther Drug Carrier Syst; 2017; 34(4):283-316. PubMed ID: 29199587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing Nanovaccines for Effective Immunization─A Special Concern on COVID-19: Facts, Fidelity, and Future Prospective.
    Gholap AD; Gupta J; Kamandar P; Bhowmik DD; Rojekar S; Faiyazuddin M; Hatvate NT; Mohanto S; Ahmed MG; Subramaniyan V; Kumarasamy V
    ACS Biomater Sci Eng; 2024 Jan; 10(1):271-297. PubMed ID: 38096426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology.
    Astorri E; Nerviani A; Bombardieri M; Pitzalis C
    Curr Pharm Des; 2015; 21(17):2216-24. PubMed ID: 25760296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanovaccine: A novel approach in immunization.
    Gheibi Hayat SM; Darroudi M
    J Cell Physiol; 2019 Aug; 234(8):12530-12536. PubMed ID: 30633361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology as a promising platform for rheumatoid arthritis management: Diagnosis, treatment, and treatment monitoring.
    Rahimizadeh P; Rezaieyazdi Z; Behzadi F; Hajizade A; Lim SI
    Int J Pharm; 2021 Nov; 609():121137. PubMed ID: 34592396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical nanocarriers for management of Rheumatoid Arthritis: A review.
    Anita C; Munira M; Mural Q; Shaily L
    Biomed Pharmacother; 2021 Sep; 141():111880. PubMed ID: 34328101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.
    Grimaudo MA
    Adv Exp Med Biol; 2021; 1295():303-315. PubMed ID: 33543465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising role of polymeric nanoparticles in the treatment of rheumatoid arthritis.
    Siddique R; Mehmood MH; Haris M; Saleem A; Chaudhry Z
    Inflammopharmacology; 2022 Aug; 30(4):1207-1218. PubMed ID: 35524837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Potential of Nanocarriers in the Management of Rheumatoid Arthritis.
    Mittal V; Sharma A; Sharma D
    Curr Rheumatol Rev; 2024 Jul; ():. PubMed ID: 39082179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nano toolbox in immune modulation and nanovaccines.
    Azharuddin M; Zhu GH; Sengupta A; Hinkula J; Slater NKH; Patra HK
    Trends Biotechnol; 2022 Oct; 40(10):1195-1212. PubMed ID: 35450779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanovaccines and their mode of action.
    Zaman M; Good MF; Toth I
    Methods; 2013 May; 60(3):226-31. PubMed ID: 23623821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.